Hereditary Cancer Testing Market To Reach $14.45 Billion By 2033

Hereditary Cancer Testing Market Growth & Trends

The global hereditary cancer testing market size is expected to reach USD 14.45 billion by 2033, and is projected to grow at a CAGR of 13.76% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is accelerating, due to government support and healthcare funding and growth of direct-to-consumer (DTC) genetic testing platforms. Hereditary cancer accounts overall to 10% and remaining 90% is sporadic cancer. There arises a need to address this growing demand of hereditary cancer which may be possible by government initiatives and funding to meet the healthcare demand. Government initiatives and funding aim at cancer prevention and genetic research significantly drive the hereditary cancer testing market.

Many countries have introduced policies that promote genetic testing as part of cancer risk assessment programs, often providing financial support for testing costs. For example, the National Comprehensive Cancer Network (NCCN), in January 2025, released a new resource designed to provide individuals with the most up-to-date recommendations on hereditary and familial cancer risks. These guidelines focus on hereditary breast, ovarian, pancreatic and prostate cancer which is available also through and app. It offers clear, easy-to-understand guidance on how to assess and test for inherited genetic mutations that may increase the risk of cancer. The information is available in a straightforward and accessible way for better comprehension.

Regulatory approvals for hereditary cancer testing ensures that genetic tests used to assess cancer risk meet rigorous standards for accuracy, safety, and reliability. The FDA classifies these tests as medical devices, and they must undergo thorough evaluation before receiving approval for market use. U.S. Food and Drug Administration (FDA) in September 2023, granted its first-ever marketing authorization for a DNA test designed to assess the genetic predisposition to multiple types of cancer. This groundbreaking approval can access multiple variant genes through next generation sequencing (NGS) which are linked to an increased risk of several cancers, including breast, ovarian, and colorectal cancers to provide insights with sensitivity, speed and accuracy. By identifying these inherited genetic mutations, the test provides individuals with valuable information to guide early detection, preventive measures, and personalized treatment plans. This approval marks a significant milestone in the field of genetic testing and cancer prevention, empowering individuals to take proactive steps toward managing their health.

Recognizing the potential of genetic testing in revolutionizing healthcare, government launches several initiatives aimed at integrating genetic services into the public health infrastructure. One significant stride taken by National Cancer Institute that awarded USD 3.2 million grant to researchers at Georgetown University's Lombardi Comprehensive Cancer Center and the Rutgers Cancer Institute of New Jersey. This funding supports a five-year study enrolling 428 Black cancer patients who meet national guidelines for hereditary cancer testing into a randomized controlled trial and will evaluate the impact of these interventions on genetic education engagement, testing uptake, informed decision-making, and psychosocial outcomes. By addressing barriers to genetic testing and incorporating community input, the research aimed at improving access to screening, and medical management of cancers, ultimately advancing health equity in oncology care.

The market has been witnessing activity of the key players such as Myriad Genetics, Inc., Bio-Rad Laboratories, F. HOFFMANN-LA ROCHE LTD and Illumina, Inc. these players are actively engaged in seeking product approvals from USFDA to meet the need of global customers. For instance, in June 2024, Myriad Genetics, Inc., announced its ongoing innovations: MyChoice CDx HRD and BRACAnalysis CDx Germline Companion Diagnostic Tests for enhancing its product portfolio through research collaborations. Additionally, Myriad has initiated multiple research collaborations to investigate the potential of MRD in various cancers. Furthermore, developments in precision medicine online screening tools for cancer enable patient education for improved outcomes. For instance, in January 2025, Myriad Genetics, Inc., announced a study showing that patients were more likely to complete hereditary cancer testing when using an online screening tool combined with genetic education. This approach highlights the importance of digital tools and education in increasing engagement and participation in genetic testing for cancer risk assessment.

Thus, technological advancements in genetic testing, growing government initiatives and funding support and accelerated regulatory approvals are boosting the market growth for early detection and disease prevention.

 Request a free sample copy or view report summary: Hereditary Cancer Testing Market Report

Hereditary Cancer Testing Market Report Highlights

• The breast cancer dominated the market with the largest revenue share of 11.88% and was among the fastest growing in this segment with a CAGR of 14.37% in 2024.

• The molecular testing segment held the highest position, accounting for the largest share of 56.43% in 2024.

• The predictive test accounted for the largest share of 66.55% and was among the fastest-growing tests in the segment for the year 2024.

• The hospitals dominated the end use segments with the largest market share of 55.17% in 2024 and were the fastest growing among the other segments over the period.

• The North America hereditary cancer testing market held the largest global revenue share of 46.14% in 2024.

Hereditary Cancer Testing Market Segmentation

Grand View Research has segmented the global hereditary cancer testing market on the basis of cancer, technology, test type, end use, and region:

Hereditary Cancer Testing by Cancer Outlook (Revenue, USD Million, 2021 - 2033)

• Lung Cancer

• Breast Cancer

• Colorectal Cancer

• Cervical Cancer

• Ovarian Cancer

• Prostate Cancer

• Stomach/Gastric Cancer

• Melanoma

• Sarcoma

• Uterine Cancer

• Pancreatic Cancer

• Others

Hereditary Cancer Testing Technology Outlook (Revenue, USD Million, 2021 - 2033)

• Cytogenetic

• Biochemical

• Molecular Testing

Hereditary Cancer Test Type Outlook (Revenue, USD Million, 2021 - 2033)

• Predictive Testing

• Diagnostic Testing

Hereditary Cancer Testing End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Diagnostic Centers

• Hospitals

• Clinics

Hereditary Cancer Testing Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players in the Hereditary Cancer Testing Market

• Myriad Genetics,

• Invitae Corporation

• Bio-Rad Laboratories

• CSL Ltd

• Qiagen NV

• Danaher Corporation

• Thermo Fisher Scientific

• Abbott Laboratories

• EUROFINS SCIENTIFIC

• F. HOFFMANN-LA ROCHE LTD

• Illumina, Inc.